• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.

作者信息

Katsios Christos, Ziogas Dimosthenis E, Roukos Dimitrios H

出版信息

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.

DOI:10.1586/egh.10.62
PMID:20932136
Abstract
摘要

相似文献

1
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.结直肠癌：西妥昔单抗、KRAS、BRAF、PIK3CA突变及其他相关研究
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.
2
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.KRAS、NRAS、BRAF、PIK3CA和PTEN对转移性结直肠癌抗表皮生长因子受体治疗的预测价值：一项系统评价和荟萃分析。
Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25.
3
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?EGAPP 工作组的建议：在转移性结直肠癌患者中检测 EGFR 通路下游效应基因的突变，能否通过指导抗 EGFR 治疗决策来改善健康结局？
Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.
4
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.结直肠癌患者综合治疗中的预测和预后因素。
Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.
5
[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].[基因变异（KRAS、BRAF、PIK3CA）与抗表皮生长因子受体抗体的临床获益]
Nihon Rinsho. 2011 Apr;69 Suppl 3:477-81.
6
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.常见突变对转移性结直肠癌患者治疗反应和生存的预后及预测价值。
Br J Cancer. 2009 Aug 4;101(3):465-72. doi: 10.1038/sj.bjc.6605164. Epub 2009 Jul 14.
7
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.BRAF、KRAS 和 PI3KCA 突变的联合致癌途径特征可改善结直肠癌分类和西妥昔单抗治疗预测。
Gut. 2013 Apr;62(4):540-9. doi: 10.1136/gutjnl-2012-302423. Epub 2012 Jul 14.
8
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.甲磺酸加贝酯对携带 KRAS、BRAF 和 PIK3CA 突变的结肠癌细胞的抗肿瘤作用。
PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24.
9
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].[转移性结直肠癌中表皮生长因子受体靶向治疗的分子预测标志物]
Cesk Patol. 2011 Oct;47(4):154-8.
10
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

引用本文的文献

1
Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.使用 64Cu 标记的西妥昔单抗正电子发射断层扫描预测 KRAS 野生型和 KRAS 突变型结直肠癌中的西妥昔单抗蓄积。
Cancer Sci. 2012 Mar;103(3):600-5. doi: 10.1111/j.1349-7006.2011.02166.x. Epub 2011 Dec 23.
2
Laparoscopic low anterior resection with total mesorectal excision for rectal cancer.腹腔镜低位前切除术联合全直肠系膜切除术治疗直肠癌。
Surg Endosc. 2012 Feb;26(2):578-9. doi: 10.1007/s00464-011-1893-9.
3
Single-incision laparoscopic surgery for colorectal cancer.
结直肠癌的单孔腹腔镜手术
Surg Endosc. 2011 Aug;25(8):2764-5. doi: 10.1007/s00464-011-1621-5.
4
Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility?将表皮生长因子血浆水平与接受微创治疗的结直肠癌患者的预后和治疗反应相关联：它具有临床实用性吗？
Surg Endosc. 2011 Aug;25(8):2766-7; author reply 2768. doi: 10.1007/s00464-011-1622-4.
5
Optimizing preoperative management of rectal cancer.优化直肠癌的术前管理。
World J Surg. 2011 Jun;35(6):1416-7; author reply 1418-9. doi: 10.1007/s00268-010-0930-5.
6
Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.术前使用西妥昔单抗后的组织学及术后即时结果：病例匹配对照研究
World J Surg. 2011 May;35(5):1153-4. doi: 10.1007/s00268-010-0915-4.
7
Clinicopathologic characteristics of colorectal cancer patients with synchronous and metachronous gastric cancer.
World J Surg. 2011 Mar;35(3):700-1. doi: 10.1007/s00268-010-0868-7.
8
Nonepithelial, submucosal gastric tumors: is laparoscopic wedge resection the optimal treatment?非上皮性胃黏膜下肿瘤：腹腔镜楔形切除术是最佳治疗方法吗？
Surg Endosc. 2011 Jun;25(6):2052-3; author reply 2054. doi: 10.1007/s00464-010-1447-6.
9
Exploring indications for laparoscopic primary tumor resection in metastatic colorectal cancer.
Surg Endosc. 2011 May;25(5):1706-7. doi: 10.1007/s00464-010-1446-7.
10
Simultaneous resection of primary colorectal cancer and synchronous liver metastases.同时切除原发性结直肠癌和同步性肝转移瘤。
World J Surg. 2011 Apr;35(4):926-7; author reply 928. doi: 10.1007/s00268-010-0833-5.